Highest-rated stocks similar to ANIX by NexusTrade rating

Ratings and dated fundamentals

Inspect a rated peer

How these companies are related

Peer membership comes from the same related-company provider used by NexusTrade's stock research. The provider identifies related companies using news coverage and returns data. A related company can be a competitor or a thematic peer; this list does not imply identical products or financial exposure.

Peer membership was fetched 2026-10-12.

The rating determines the order after peer membership is selected. The anchor company is excluded. Companies without an eligible report rating or dated fundamentals are counted in coverage and left out of the ranked table.

What best means in this list

This list was refreshed on 2026-11-07 using existing company reports. The report date in each row is the date of the underlying analysis; refreshing the list does not create a new company report.

Best means the highest stored NexusTrade report ratings within this selection. Ratings use the product's 1-to-5 scale. The list sorts by rating from high to low, with ticker order breaking equal-rating ties. A rating summarizes a report; it does not predict a stock's return.

The peer set comes from the recorded related-company provider. Similarity defines which companies enter this comparison; it does not establish that they have equal business models, risk or expected returns.

What the leading companies do

The first 5 companies below lead the ratings in this snapshot; equal ratings are ordered by ticker. Their company profiles describe different businesses even when they share the Anixa Biosciences, Inc. (ANIX) selection.

These are company descriptions, not estimates of revenue from this theme. Industry membership does not identify a pure-play business or establish how much sales depend on it. Open the company profile and examine segment disclosures before treating an overlapping classification as equivalent exposure.

1. Exelixis Inc (EXEL): 4 / 5

   Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an ADC consisting of a MMAE payload conjugated to a human mAb targeting the tumor antigen 5T4; and XL495, a small molecule inhibitor of PKMYT1. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent Pharma Solutions, Inc.; Iconic Therapeutics, Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

2. Incyte Genomics Inc (INCY): 3.5 / 5

   Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

3. PUMA BIOTECHNOLOGY INC (PBYI): 3.5 / 5

   Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

4. Bristol-Myers Squibb Co. (BMY): 3 / 5

   Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

5. GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK): 3 / 5

   GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom.

Valuation and company size within this selection

These summaries use the 92 displayed companies. Each company retains its own market observation date in the ratings table above. Medians are unweighted; they are not a sector index valuation.

Positive P/E and price-to-book values are summarized separately. Missing, zero and negative values are excluded from those medians, with the included count shown. A lower multiple alone does not establish better value: profitability, growth, debt and business mix can differ.

Other business classifications in the list

A company can appear in several product and revenue classifications. These overlapping memberships help identify different business mixes to investigate; they are not verified revenue shares or mutually exclusive subindustries.

Dates and coverage

Report dates range from 2025-12-31 to 2025-12-31. Market observations range from 2026-11-06 to 2026-11-06. These dates may differ across companies. Daily closes are not synchronized live quotes.

The selection includes 0 companies without a report, 0 with invalid latest rating metadata, 0 with older reports, 3 with missing required fundamentals and 0 with out-of-date market observations. Missing companies receive no substitute score.

How the ranking is built

The ranking uses the latest stored report at or before the refresh cutoff for each active eligible company. The report date, fiscal year/period and producing model remain visible. The latest invalid score is excluded; an older favorable score does not replace it. Publication policy stock-ratings-v1 accepts report ages up to 550 days and market observations up to 10 calendar days, with a positive close and market capitalization. Optional missing ratios remain not reported.

Report ages can differ substantially, particularly between annual and quarterly reports. Different producing models may also use different judgments. Read the date, fiscal period and model before comparing scores. Private report analysis and account data are not published here.

A refresh reads existing reports and market data. It does not rerun a model or create a new analysis. Compare business fundamentals and your own research constraints alongside the score before making a decision.